Relapsed Multiple Myeloma Clinical Trial
Official title:
Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use
This retrospective multicenter observational study will provide real-life efficacy and tolerance data for patients with relapsed multiple myeloma (RMM) treated with carfilzomib in the context of nominative expanded access and compassionate use in France, and will allow to evaluate healthcare practices from data obtained during the use of carfilzomib for routine care. Nominative expanded access was open in February 2014 and stopped in march 2016, then relayed by the compassionate program (march 2016- February 2017).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04083534 -
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06119685 -
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05577000 -
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01118689 -
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
|
Phase 1 | |
| Withdrawn |
NCT04802031 -
Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT02401295 -
ATRA, Celecoxib, and Itraconazole as Maintenance
|
Phase 1 | |
| Active, not recruiting |
NCT00603447 -
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
|
Phase 1 | |
| Active, not recruiting |
NCT02722668 -
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
|
Phase 2 | |
| Active, not recruiting |
NCT04965155 -
A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)
|
Phase 2 | |
| Completed |
NCT00592579 -
A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma
|
Phase 2 | |
| Not yet recruiting |
NCT06433947 -
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT06304636 -
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT03158688 -
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
|
Phase 3 | |
| Completed |
NCT04434469 -
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01080391 -
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
|
Phase 3 | |
| Not yet recruiting |
NCT06348108 -
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT01949532 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
|
Phase 1 | |
| Active, not recruiting |
NCT04398485 -
A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT03091933 -
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
|
Phase 1/Phase 2 | |
| Completed |
NCT01272466 -
Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma
|
Phase 1/Phase 2 |